Cardiac-specific disruption of gh receptor alters glucose homeostasis while maintaining normal cardiac performance in adult male mice

Endocrinology

Volumn 157, Issue 5, 2016, Pages 1929-1941

  Jara, Adam ^a,b   Liu, Xingbo ^a,e   Sim, Don ^a   Benner, Chance M ^a,e   Duran Ortiz, Silvana ^a,d   Qian, Yanrong ^a   List, Edward O ^a,c   Berryman, Darlene E ^a,b,e   Kim, Jason K ^b,f   Kopchick, John J ^a,d  

^a OHIO UNIVERSITY   (United States)

^b Departments of Biomedical Sciences   (United Kingdom)

^c OHIO UNIVERSITY   (United States)

^d Department of Biological Sciences   (United States)

^e Sciences and Wellness   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CRE RECOMBINASE; DOBUTAMINE; GROWTH HORMONE RECEPTOR; INSULIN; PROTEIN KINASE B; SOMATOMEDIN C; TAMOXIFEN; GLUCOSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; CARDIAC MUSCLE; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXERCISE TEST; FAT MASS; GENE DISRUPTION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEART; HEART DEVELOPMENT; HEART FUNCTION; HEART PERFORMANCE; IMMUNOBLOTTING; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; WHITE ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; GENETICS; HOMEOSTASIS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE, WHITE; ANIMALS; BODY COMPOSITION; GLUCOSE; HEART; HOMEOSTASIS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 84969794953     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1686     Document Type: Article

References (55)

1. Bruel A, Oxlund H. Biosynthetic growth hormone increases the collagen deposition rate in rat aorta and heart. Eur J Endocrinol. 1995;132(2):195-199.
2. Rubin SA, Buttrick P, Malhotra A, Melmed S, FishbeinMC. Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Mol Cell Cardiol. 1990;22(4):429-438.
3. Xu XP, Best PM. Decreased transient outward K current in ventricular myocytes from acromegalic rats. Am J Physiol. 1991;260(3 Pt 2):H935-H942.
4. Solem ML, Thomas AP. Modulation of cardiac Ca2 channels by IGF1. Biochem Biophys Res Commun. 1998;252(1):151-155.
5. Colao A. The GH-IGF-1 axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008;69(3):347-358.
6. Castellano G, Affuso F, Conza PD, Fazio S. The GH/IGF-1 axis and heart failure. Curr Cardiol Rev. 2009;5(3):203-215.
7. Colao A, Somma CD, Savanelli MC, Leo MD, LombarDi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency andGHtherapy. Growth Horm IGF Res. 2006;16(suppl A):S41-S48.
8. Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol. 2000;85(2):209-213.
9. Ben-Dov I, Gaides M, Scheinowitz M, Wagner R, Laron Z. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol (Oxf). 2003;59(6): 763-767.
10. Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides. 2002;36(2-3):201-208.
11. Bollano E, Omerovic E, Bohlooly-y M, et al. Impairment of cardiac function and bioenergetics in adult transgenic mice overexpressing the bovine growth hormone gene. Endocrinology. 2000;141(6): 2229-2235.
12. Dilley RJ, Schwartz SM. Vascular remodeling in the growth hormone transgenic mouse. Circ Res. 1989;65(5):1233-1240.
13. Peten EP, Striker LJ, Fogo A, Ichikawa I, Patel A, Striker GE. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Mol Med. 1994;1(1):104-115.
14. Izzard AS, Emerson M, Prehar S, et al. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res. 2009;19(5):413-419.
15. Bohlooly-y M, Carlson L, Olsson B, et al. Vascular function and blood pressure inGHtransgenic mice. Endocrinology. 2001;142(8): 3317-3323.
16. Jara A, Benner CM, Sim D, et al. Elevated systolic blood pressure in male GH transgenic mice is age dependent. Endocrinology. 2014; 155(3):975-986.
17. Colligan PB, Brown-Borg HM, Duan J, Ren BH, Ren J. Cardiac contractile function is enhanced in isolated ventricular myocytes from growth hormone transgenic mice. J Endocrinol. 2002;173(2): 257-264.
18. Bonkowski MS, Rocha JS, Masternak MM, Regaiey KAA, Bartke A. Targeted disruption of growth hormone receptor interferes with the beneficial actions of calorie restriction. Proc Natl Acad Sci USA. 2006;103(20):7901-7905.
19. Egecioglu E, Andersson IJ, Bollano E, et al. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function. Am J Physiol Metab. 2007; 292(5):E1418-E1425.
20. Sohal DS, Nghiem M, Crackower MA, et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001; 89(1):20-25.
21. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol (Baltimore, Md). 2013;27(3):524-535.
22. Andersson KB, Winer LH, Mork HK, Molkentin JD, Jaisser F. Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts. Transgenic Res. 2010;19(4): 715-725.
23. Palmer AJ, Chung MY, List EO, et al. Age-related changes in body composition of bovine growth hormone transgenic mice. Endocrinology. 2009;150(3):1353-1360.
24. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-622.
25. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binDing protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94(24):13215-13220.
26. Giani JF, Bonkowski MS, Munoz MC, et al. Insulin signaling cascade in the hearts of long-lived growth hormone receptor knockout mice: effects of calorie restriction. J Gerontol Biol SciMedSci. 2008; 63(8):788-797.
27. Kim J, Wende AR, Sena S, et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol (Baltimore, Md). 2008;22(11):2531-2543.
28. Moellendorf S, Kessels C, Peiseler L, et al. IGF-1R signaling attenuates the age-related decline of diastolic cardiac function. Am J Physiol Metab. 2012;303(2):E213-E222.
29. Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest. 2002;109(5):629-639.
30. Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation. 2009;119(9):1272-1283.
31. Bugger H, Riehle C, Jaishy B, et al. Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Mol Cell Cardiol. 2012; 52(5):1019-1026.
32. Laustsen PG, Russell SJ, Cui L, et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol. 2007;27(5):1649-1664.
33. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA. 2008;105(49):19378-19383.
34. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96(13):7324-7329.
35. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-1) is the principal source of IGF-1 in blood but is not required for postnatal body growth in mice. Proc Natl Acad SciUSA. 1999;96(12):7088-7092.
36. List EO, Berryman DE, Funk K, et al. Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-1, increased local IGF-1, and altered body size, body composition, and adipokine profiles. Endocrinology. 2014;155(5):1793-1805.
37. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284(30): 19937-19944.
38. Slaaby R, Schäffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-1R) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006;281(36):25869-25874.
39. Grueter CE, van Rooij E, Johnson BA, et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149(3):671-683.
40. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation. 2012;126(21):e327-e332.
41. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30(2):152-177.
42. Randle PJ, Priestman DA, Mistry SC, Halsall A. Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem. 1994;55(suppl):1-11.
43. Cook SA, Varela-Carver A, Mongillo M, et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010;31(1):100-111.
44. Kim J-H, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613-633.
45. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31(2):391-398.
46. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56(2):225-231.
47. BarnesKM,Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci. 2009;10(1):96-107.
48. McManus DD, Lyass A, Ingelsson E, et al. Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study. Obes (Silver Spring, Md). 2012;20(9): 1882-1886.
49. Kim M, OH JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45(2):270-280.
50. Bers DM, Eisner DA, Valdivia HH. Sarcoplasmic reticulum Ca2 and heart failure: roles of diastolic leak and Ca2 transport. Circ Res. 2003;93(6):487-490.
51. Koitabashi N, Bedja D, Zaiman AL, et al. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res. 2009;105(1):12-15.
52. Vijayakumar A,WuY, Sun H, et al. Targeted loss ofGHRsignaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes. 2012;61(1):94-103.
53. List EO, Berryman DE, Ikeno Y, et al. Removal of growth hormone receptor (GHR) in muscle of male mice replicates some of the health benefits seen in global GHR-/ mice. Aging. 2015;7(7):500-512.
54. MavalliMD,Digirolamo DJ, Fan Y, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010;120(11):4007-4020.
55. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development (Cambridge, England). 2007; 134(23):4131-4140.